Awaiting development: Guidance and quality standards

Showing 281 to 290 of 332

Guidance and quality standards awaiting development
Title	Type
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]	Technology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]	Technology appraisal guidance
Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]	Technology appraisal guidance
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]	Technology appraisal guidance
Tildrakizumab for treating active psoriatic arthritis [ID6724]	Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]	Technology appraisal guidance
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]	Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]	Technology appraisal guidance
Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]	Technology appraisal guidance
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [ID6733]	Technology appraisal guidance